Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

36.22
+0.35771.00%
Post-market: 36.16-0.0550-0.15%19:30 EDT
Volume:3K
Turnover:90.56K
Market Cap:88.01M
PE:- -
High:36.23
Open:36.18
Low:35.96
Close:35.86
52wk High:39.48
52wk Low:33.59
Shares:2.43M
Float Shares:2.43M
Volume Ratio:0.36
T/O Rate:0.10%
Dividend:0.33
Dividend Rate:0.91%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30